RU2467008C2 - СОЕДИНЕНИЯ ИМИДАЗО[1,2-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ РЕЦЕПТОРНЫХ ТИРОЗИНКИНАЗ - Google Patents
СОЕДИНЕНИЯ ИМИДАЗО[1,2-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ РЕЦЕПТОРНЫХ ТИРОЗИНКИНАЗ Download PDFInfo
- Publication number
- RU2467008C2 RU2467008C2 RU2009140407/04A RU2009140407A RU2467008C2 RU 2467008 C2 RU2467008 C2 RU 2467008C2 RU 2009140407/04 A RU2009140407/04 A RU 2009140407/04A RU 2009140407 A RU2009140407 A RU 2009140407A RU 2467008 C2 RU2467008 C2 RU 2467008C2
- Authority
- RU
- Russia
- Prior art keywords
- pyridin
- imidazo
- yloxy
- compound
- methoxyethoxy
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 150000005234 imidazo[1,2-a]pyridines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 60
- 238000000034 method Methods 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 229910052731 fluorine Inorganic materials 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 229910052801 chlorine Inorganic materials 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 7
- -1 2-pyrimidyl Chemical group 0.000 claims 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 7
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 5
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 4
- 230000003993 interaction Effects 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 2
- 125000006242 amine protecting group Chemical group 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims 2
- LJSSJGXMPSLSIR-NHCUHLMSSA-N (3r,4r)-4-[2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]oxypiperidin-3-ol Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2O[C@@H]1CCNC[C@H]1O LJSSJGXMPSLSIR-NHCUHLMSSA-N 0.000 claims 1
- LHOJRSNEPLRYJS-TZIWHRDSSA-N (3r,4r)-4-[2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]oxypyrrolidin-3-ol Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2O[C@@H]1CNC[C@H]1O LHOJRSNEPLRYJS-TZIWHRDSSA-N 0.000 claims 1
- LJSSJGXMPSLSIR-RTWAWAEBSA-N (3r,4s)-4-[2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]oxypiperidin-3-ol Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2O[C@H]1CCNC[C@H]1O LJSSJGXMPSLSIR-RTWAWAEBSA-N 0.000 claims 1
- PCRCKJQVHCGZFM-SFHVURJKSA-N (3s)-3-[[2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]oxymethyl]morpholine Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2OC[C@@H]1COCCN1 PCRCKJQVHCGZFM-SFHVURJKSA-N 0.000 claims 1
- MTEYLRHKRPYBCB-YLJYHZDGSA-N 2-(7-ethylimidazo[1,2-a]pyridin-3-yl)-8-[(3r,4r)-3-fluoropiperidin-4-yl]oxyquinoline Chemical compound C=1N=C2C=C(CC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2O[C@@H]1CCNC[C@H]1F MTEYLRHKRPYBCB-YLJYHZDGSA-N 0.000 claims 1
- XZOOZZGHEVFMAJ-UHFFFAOYSA-N 2-[2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]oxyethanamine Chemical compound C1=CC=C(OCCN)C2=NC(C=3N4C=CC(=CC4=NC=3)OCCOC)=CC=C21 XZOOZZGHEVFMAJ-UHFFFAOYSA-N 0.000 claims 1
- CLEYIMMREBBHKP-YLJYHZDGSA-N 2-[3-[8-[(3r,4r)-3-fluoropiperidin-4-yl]oxyquinolin-2-yl]imidazo[1,2-a]pyridin-7-yl]oxyethanol Chemical compound C=1N=C2C=C(OCCO)C=CN2C=1C(N=C12)=CC=C1C=CC=C2O[C@@H]1CCNC[C@H]1F CLEYIMMREBBHKP-YLJYHZDGSA-N 0.000 claims 1
- XZMAHDRRCQRMHC-UHFFFAOYSA-N 2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-8-(1-methylpiperidin-4-yl)oxyquinoline Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2OC1CCN(C)CC1 XZMAHDRRCQRMHC-UHFFFAOYSA-N 0.000 claims 1
- RSFHJWJNNOAZMN-UHFFFAOYSA-N 2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-8-(2-piperidin-2-ylethoxy)quinoline Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2OCCC1CCCCN1 RSFHJWJNNOAZMN-UHFFFAOYSA-N 0.000 claims 1
- RNDLZUAZVRFLRS-UHFFFAOYSA-N 2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-8-(piperidin-3-ylmethoxy)quinoline Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2OCC1CCCNC1 RNDLZUAZVRFLRS-UHFFFAOYSA-N 0.000 claims 1
- GQNJNGOQHBAXOL-UHFFFAOYSA-N 2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-8-(piperidin-4-ylmethoxy)quinoline Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2OCC1CCNCC1 GQNJNGOQHBAXOL-UHFFFAOYSA-N 0.000 claims 1
- IQACVVFBPSXQID-UHFFFAOYSA-N 2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-8-(pyrrolidin-3-ylmethoxy)quinoline Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2OCC1CCNC1 IQACVVFBPSXQID-UHFFFAOYSA-N 0.000 claims 1
- KPBBCDRZGUBDOM-UHFFFAOYSA-N 2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-8-[(1-methylpyrrolidin-3-yl)methoxy]quinoline Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2OCC1CCN(C)C1 KPBBCDRZGUBDOM-UHFFFAOYSA-N 0.000 claims 1
- TXAFYFWHBVJGHQ-LJQANCHMSA-N 2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-8-[(3r)-piperidin-3-yl]oxyquinoline Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2O[C@@H]1CCCNC1 TXAFYFWHBVJGHQ-LJQANCHMSA-N 0.000 claims 1
- CKGYOCHUFHHZBI-GOSISDBHSA-N 2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-8-[(3r)-pyrrolidin-3-yl]oxyquinoline Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2O[C@@H]1CCNC1 CKGYOCHUFHHZBI-GOSISDBHSA-N 0.000 claims 1
- NQOAYTFDSNONAL-FGZHOGPDSA-N 2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-8-[(3r,4r)-4-methoxypyrrolidin-3-yl]oxyquinoline Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2O[C@@H]1CNC[C@H]1OC NQOAYTFDSNONAL-FGZHOGPDSA-N 0.000 claims 1
- TXAFYFWHBVJGHQ-IBGZPJMESA-N 2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-8-[(3s)-piperidin-3-yl]oxyquinoline Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2O[C@H]1CCCNC1 TXAFYFWHBVJGHQ-IBGZPJMESA-N 0.000 claims 1
- CKGYOCHUFHHZBI-SFHVURJKSA-N 2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-8-[(3s)-pyrrolidin-3-yl]oxyquinoline Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2O[C@H]1CCNC1 CKGYOCHUFHHZBI-SFHVURJKSA-N 0.000 claims 1
- XSWXDGBUKRJVOH-GOSISDBHSA-N 2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-8-[[(2r)-pyrrolidin-2-yl]methoxy]quinoline Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2OC[C@H]1CCCN1 XSWXDGBUKRJVOH-GOSISDBHSA-N 0.000 claims 1
- RROPCZKHYUPTGO-UHFFFAOYSA-N 2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-8-piperidin-4-yloxyquinoline Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2OC1CCNCC1 RROPCZKHYUPTGO-UHFFFAOYSA-N 0.000 claims 1
- IXABGGXDRTVRCC-UHFFFAOYSA-N 2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-n-(4-methylpiperidin-4-yl)quinolin-8-amine Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2NC1(C)CCNCC1 IXABGGXDRTVRCC-UHFFFAOYSA-N 0.000 claims 1
- KHQNCCQHMLMRSX-QGZVFWFLSA-N 2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-n-[(3r)-pyrrolidin-3-yl]quinolin-8-amine Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2N[C@@H]1CCNC1 KHQNCCQHMLMRSX-QGZVFWFLSA-N 0.000 claims 1
- KHQNCCQHMLMRSX-KRWDZBQOSA-N 2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]-n-[(3s)-pyrrolidin-3-yl]quinolin-8-amine Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2N[C@H]1CCNC1 KHQNCCQHMLMRSX-KRWDZBQOSA-N 0.000 claims 1
- DDRZDPGSGJJQRD-DENIHFKCSA-N 2-[7-(cyclopropylmethoxy)imidazo[1,2-a]pyridin-3-yl]-8-[(3r,4r)-3-fluoropiperidin-4-yl]oxyquinoline Chemical compound F[C@@H]1CNCC[C@H]1OC1=CC=CC2=CC=C(C=3N4C=CC(OCC5CC5)=CC4=NC=3)N=C12 DDRZDPGSGJJQRD-DENIHFKCSA-N 0.000 claims 1
- UKIMQUCEPRESKY-UHFFFAOYSA-N 2-[7-(oxan-4-yloxy)imidazo[1,2-a]pyridin-3-yl]quinoline Chemical compound O1CCC(CC1)OC1=CC=2N(C=C1)C(=CN=2)C1=NC2=CC=CC=C2C=C1 UKIMQUCEPRESKY-UHFFFAOYSA-N 0.000 claims 1
- TZIXXHVIMUUDMH-UHFFFAOYSA-N 2-[[2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]oxymethyl]morpholine Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2OCC1CNCCO1 TZIXXHVIMUUDMH-UHFFFAOYSA-N 0.000 claims 1
- OEQLYHXNGSLNQN-UHFFFAOYSA-N 3-[2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]oxy-2,2-dimethylpropan-1-amine Chemical compound C1=CC=C(OCC(C)(C)CN)C2=NC(C=3N4C=CC(=CC4=NC=3)OCCOC)=CC=C21 OEQLYHXNGSLNQN-UHFFFAOYSA-N 0.000 claims 1
- BVQNLQXIIBXKGV-UHFFFAOYSA-N 3-[2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinolin-8-yl]oxy-n,n,2,2-tetramethylpropan-1-amine Chemical compound C1=CC=C(OCC(C)(C)CN(C)C)C2=NC(C=3N4C=CC(=CC4=NC=3)OCCOC)=CC=C21 BVQNLQXIIBXKGV-UHFFFAOYSA-N 0.000 claims 1
- URCODTVVEBNHBV-WIYYLYMNSA-N 5-fluoro-8-[(3r,4r)-3-fluoropiperidin-4-yl]oxy-2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinoline Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C(F)=CC=C2O[C@@H]1CCNC[C@H]1F URCODTVVEBNHBV-WIYYLYMNSA-N 0.000 claims 1
- XSEPWAKOMGUUGZ-WIYYLYMNSA-N 6-fluoro-8-[(3r,4r)-3-fluoropiperidin-4-yl]oxy-2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinoline Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=C(F)C=C2O[C@@H]1CCNC[C@H]1F XSEPWAKOMGUUGZ-WIYYLYMNSA-N 0.000 claims 1
- ALJIWGDXJWSXQV-UHFFFAOYSA-N 8-(1-ethylpiperidin-4-yl)oxy-2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinoline Chemical compound C1CN(CC)CCC1OC1=CC=CC2=CC=C(C=3N4C=CC(OCCOC)=CC4=NC=3)N=C12 ALJIWGDXJWSXQV-UHFFFAOYSA-N 0.000 claims 1
- BZRLFTGHSYBAQK-UHFFFAOYSA-N 8-(8-azabicyclo[3.2.1]octan-3-yloxy)-2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinoline Chemical compound C1C(N2)CCC2CC1OC(C1=N2)=CC=CC1=CC=C2C1=CN=C2N1C=CC(OCCOC)=C2 BZRLFTGHSYBAQK-UHFFFAOYSA-N 0.000 claims 1
- FESXABGGTQSRQZ-DENIHFKCSA-N 8-[(3r,4r)-3-fluoro-1-methylpiperidin-4-yl]oxy-2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinoline Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2O[C@@H]1CCN(C)C[C@H]1F FESXABGGTQSRQZ-DENIHFKCSA-N 0.000 claims 1
- BHTLCFNWNNFOFE-NFBKMPQASA-N 8-[(3r,4r)-3-fluoropiperidin-4-yl]oxy-2-(7-pyridin-3-ylimidazo[1,2-a]pyridin-3-yl)quinoline Chemical compound F[C@@H]1CNCC[C@H]1OC1=CC=CC2=CC=C(C=3N4C=CC(=CC4=NC=3)C=3C=NC=CC=3)N=C12 BHTLCFNWNNFOFE-NFBKMPQASA-N 0.000 claims 1
- YYJQBDHSLHYZOC-DENIHFKCSA-N 8-[(3r,4r)-3-fluoropiperidin-4-yl]oxy-2-(7-pyrimidin-5-ylimidazo[1,2-a]pyridin-3-yl)quinoline Chemical compound F[C@@H]1CNCC[C@H]1OC1=CC=CC2=CC=C(C=3N4C=CC(=CC4=NC=3)C=3C=NC=NC=3)N=C12 YYJQBDHSLHYZOC-DENIHFKCSA-N 0.000 claims 1
- PPPOUAQYRUUFNJ-WIYYLYMNSA-N 8-[(3r,4r)-3-fluoropiperidin-4-yl]oxy-2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinoline Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2O[C@@H]1CCNC[C@H]1F PPPOUAQYRUUFNJ-WIYYLYMNSA-N 0.000 claims 1
- OPAMDWHECZQIBN-ZJSXRUAMSA-N 8-[(3r,4r)-3-fluoropiperidin-4-yl]oxy-2-[7-(4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-3-yl]quinoline Chemical compound CC1=CC=NC=C1C1=CC2=NC=C(C=3N=C4C(O[C@H]5[C@@H](CNCC5)F)=CC=CC4=CC=3)N2C=C1 OPAMDWHECZQIBN-ZJSXRUAMSA-N 0.000 claims 1
- FREBNXPQQZJEKM-WOIUINJBSA-N 8-[(3r,4r)-3-fluoropiperidin-4-yl]oxy-2-[7-[(3r)-oxolan-3-yl]oxyimidazo[1,2-a]pyridin-3-yl]quinoline Chemical compound F[C@@H]1CNCC[C@H]1OC1=CC=CC2=CC=C(C=3N4C=CC(O[C@H]5COCC5)=CC4=NC=3)N=C12 FREBNXPQQZJEKM-WOIUINJBSA-N 0.000 claims 1
- FREBNXPQQZJEKM-NNMXDRDESA-N 8-[(3r,4r)-3-fluoropiperidin-4-yl]oxy-2-[7-[(3s)-oxolan-3-yl]oxyimidazo[1,2-a]pyridin-3-yl]quinoline Chemical compound F[C@@H]1CNCC[C@H]1OC1=CC=CC2=CC=C(C=3N4C=CC(O[C@@H]5COCC5)=CC4=NC=3)N=C12 FREBNXPQQZJEKM-NNMXDRDESA-N 0.000 claims 1
- PPPOUAQYRUUFNJ-NQIIRXRSSA-N 8-[(3r,4s)-3-fluoropiperidin-4-yl]oxy-2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinoline Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2O[C@H]1CCNC[C@H]1F PPPOUAQYRUUFNJ-NQIIRXRSSA-N 0.000 claims 1
- LWHKFZNLONZVNC-WMZHIEFXSA-N 8-[(3r,4s)-4-fluoropyrrolidin-3-yl]oxy-2-(7-pyridin-3-ylimidazo[1,2-a]pyridin-3-yl)quinoline Chemical compound F[C@H]1CNC[C@H]1OC1=CC=CC2=CC=C(C=3N4C=CC(=CC4=NC=3)C=3C=NC=CC=3)N=C12 LWHKFZNLONZVNC-WMZHIEFXSA-N 0.000 claims 1
- SXFXTYDCDKSPCU-LAUBAEHRSA-N 8-[(3r,4s)-4-fluoropyrrolidin-3-yl]oxy-2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinoline Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2O[C@@H]1CNC[C@@H]1F SXFXTYDCDKSPCU-LAUBAEHRSA-N 0.000 claims 1
- PPPOUAQYRUUFNJ-RXVVDRJESA-N 8-[(3s,4s)-3-fluoropiperidin-4-yl]oxy-2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinoline Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2O[C@H]1CCNC[C@@H]1F PPPOUAQYRUUFNJ-RXVVDRJESA-N 0.000 claims 1
- OUJDQQBZGPBOKT-UHFFFAOYSA-N 8-[(4-fluoropiperidin-4-yl)methoxy]-2-[7-(2-methoxyethoxy)imidazo[1,2-a]pyridin-3-yl]quinoline Chemical compound C=1N=C2C=C(OCCOC)C=CN2C=1C(N=C12)=CC=C1C=CC=C2OCC1(F)CCNCC1 OUJDQQBZGPBOKT-UHFFFAOYSA-N 0.000 claims 1
- CEECEQWHEAERFB-UHFFFAOYSA-N 8-piperidin-4-yloxy-2-(7-pyridin-3-ylimidazo[1,2-a]pyridin-3-yl)quinoline Chemical compound C1CNCCC1OC1=CC=CC2=CC=C(C=3N4C=CC(=CC4=NC=3)C=3C=NC=CC=3)N=C12 CEECEQWHEAERFB-UHFFFAOYSA-N 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 239000007822 coupling agent Substances 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 229910052763 palladium Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000003444 phase transfer catalyst Substances 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 0 Bc1c(*)c2nc(*)c(-c3c(*)c(*)c(c(*)c(*)c(*)c4OC(*CC(C)N(*)C5)C5O)c4n3)[n]2c(C)c1* Chemical compound Bc1c(*)c2nc(*)c(-c3c(*)c(*)c(c(*)c(*)c(*)c4OC(*CC(C)N(*)C5)C5O)c4n3)[n]2c(C)c1* 0.000 description 1
- PAXANHPWDOGPQX-UHFFFAOYSA-N Cc(cc1)ccc1S(C[N+]#C)(=O)=O Chemical compound Cc(cc1)ccc1S(C[N+]#C)(=O)=O PAXANHPWDOGPQX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90985707P | 2007-04-03 | 2007-04-03 | |
| US60/909,857 | 2007-04-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009140407A RU2009140407A (ru) | 2011-05-10 |
| RU2467008C2 true RU2467008C2 (ru) | 2012-11-20 |
Family
ID=39539641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009140407/04A RU2467008C2 (ru) | 2007-04-03 | 2008-03-27 | СОЕДИНЕНИЯ ИМИДАЗО[1,2-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ РЕЦЕПТОРНЫХ ТИРОЗИНКИНАЗ |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8138181B2 (enExample) |
| EP (1) | EP2137184B1 (enExample) |
| JP (1) | JP5374492B2 (enExample) |
| KR (1) | KR101538179B1 (enExample) |
| CN (2) | CN101679423A (enExample) |
| AU (1) | AU2008237507B2 (enExample) |
| BR (1) | BRPI0809998B8 (enExample) |
| CA (1) | CA2682981C (enExample) |
| CO (1) | CO6251377A2 (enExample) |
| CY (1) | CY1114277T1 (enExample) |
| DK (1) | DK2137184T3 (enExample) |
| ES (1) | ES2420113T3 (enExample) |
| HR (1) | HRP20130660T1 (enExample) |
| IL (1) | IL201300A0 (enExample) |
| MX (1) | MX2009010728A (enExample) |
| MY (1) | MY157724A (enExample) |
| NZ (1) | NZ580327A (enExample) |
| PL (1) | PL2137184T3 (enExample) |
| PT (1) | PT2137184E (enExample) |
| RS (1) | RS52862B (enExample) |
| RU (1) | RU2467008C2 (enExample) |
| TW (1) | TWI429434B (enExample) |
| UA (1) | UA101611C2 (enExample) |
| WO (1) | WO2008124323A1 (enExample) |
| ZA (1) | ZA200907674B (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3838903B1 (en) | 2005-12-13 | 2023-11-22 | Incyte Holdings Corporation | Pyrrolo[2,3-d]pyrimidine derivative as janus kinase inhibitor |
| US8513276B2 (en) | 2006-12-22 | 2013-08-20 | Astex Therapeutics Limited | Imidazo[1,2-a]pyridine compounds for use in treating cancer |
| CN101679408B (zh) | 2006-12-22 | 2016-04-27 | Astex治疗学有限公司 | 作为fgfr抑制剂的双环杂环化合物 |
| CN101932582B (zh) | 2007-06-13 | 2013-09-25 | 因塞特公司 | 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐 |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
| CA3034994A1 (en) | 2008-06-03 | 2009-12-10 | Intermune, Inc. | Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| SI2350075T1 (sl) | 2008-09-22 | 2014-06-30 | Array Biopharma, Inc. | Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji |
| WO2010039825A2 (en) * | 2008-10-01 | 2010-04-08 | Array Biopharma Inc. | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS |
| ES2900243T3 (es) | 2008-10-22 | 2022-03-16 | Array Biopharma Inc | Compuestos de pirazolo[1,5-a]pirimidina sustituidos como inhibidores de trk quinasa |
| GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| US8716303B2 (en) | 2009-05-22 | 2014-05-06 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| RS59632B1 (sr) | 2009-05-22 | 2020-01-31 | Incyte Holdings Corp | 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- ili heptan-nitril kao jak inhibitori |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| KR101774035B1 (ko) | 2009-10-30 | 2017-09-01 | 얀센 파마슈티카 엔.브이. | 이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도 |
| FR2953838B1 (fr) * | 2009-12-10 | 2012-02-24 | Sanofi Aventis | Derives de 9h-beta-carboline (ou 9h-pyridino[3,4-b]indole) trisubstitues, leur preparation et leur utilisation therapeutique |
| FR2953837B1 (fr) * | 2009-12-10 | 2012-03-09 | Sanofi Aventis | Derives 9h-pyridino[3,4-b]indole disubstitues, leur preparation et leur utilisation therapeutique |
| MX2012007329A (es) * | 2009-12-21 | 2012-10-15 | Array Biopharma Inc | Compuestos de n-(1h-indazol-4-il) imidazo [1, 2-a] piridin-3-carboxamida substituida como inhibidores de cfms. |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| ME02386B (me) | 2010-03-10 | 2016-09-20 | Incyte Holdings Corp | Derivati piperidin-4-il azetidina kao inhibitori jak1 |
| EP2565185A1 (en) * | 2010-04-28 | 2013-03-06 | Daiichi Sankyo Company, Limited | [5,6]heterocyclic compound |
| MX2012013467A (es) | 2010-05-20 | 2013-04-29 | Array Biopharma Inc | Compuestos macrociclicos como inhibidores de trk cinasa. |
| NZ603686A (en) | 2010-05-21 | 2014-11-28 | Incyte Corp | Topical formulation for a jak inhibitor |
| JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
| TW201249845A (en) | 2010-11-19 | 2012-12-16 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| RS54070B1 (sr) * | 2010-12-13 | 2015-10-30 | Array Biopharma Inc. | SUPSTITUISANA N-(1H-INDAZOL-4-IL)IMIDAZO[1,2-a]PIRIDIN-3-KARBOKSAMIDNA JEDINJENJA KAO INHIBITORI TIPA III RECEPTORA TIROZIN KINAZE |
| CN103492377B (zh) * | 2011-02-25 | 2016-04-20 | 阵列生物制药公司 | 作为pim激酶抑制剂的三唑并吡啶化合物 |
| KR20140040819A (ko) | 2011-06-20 | 2014-04-03 | 인사이트 코포레이션 | Ｊａｋ 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체 |
| US10604523B2 (en) | 2011-06-27 | 2020-03-31 | Janssen Pharmaceutica Nv | 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives |
| WO2013005057A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | New compounds |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| CN103214481B (zh) * | 2012-01-21 | 2016-08-03 | 中国科学院上海药物研究所 | 新型咪唑并[1,2-a]吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途 |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| JP6426603B2 (ja) | 2012-06-26 | 2018-11-21 | ヤンセン ファーマシューティカ エヌ．ベー． | 神経障害または代謝障害の治療に使用するための、１−アリール−４−メチル−［１，２，４］トリアゾロ［４，３−ａ］−キノキサリン化合物などのＰＤＥ２阻害剤とＰＤＥ１０阻害剤との組合せ |
| EP2869822B1 (en) | 2012-07-09 | 2016-09-14 | Janssen Pharmaceutica, N.V. | Inhibitors of phosphodiesterase 10 enzyme |
| JP6430383B2 (ja) * | 2012-09-28 | 2018-11-28 | ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ | 選択的ｂｍｐ阻害剤としての縮合複素環化合物 |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| WO2014078331A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US10166191B2 (en) | 2012-11-15 | 2019-01-01 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| TW201932456A (zh) | 2013-01-15 | 2019-08-16 | 美商英塞特控股公司 | 適用作pim激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物 |
| DK2964650T3 (en) | 2013-03-06 | 2019-02-11 | Incyte Holdings Corp | PROCEDURES AND INTERMEDIATES FOR THE MANUFACTURE OF A JAK INHIBITOR |
| US9394254B2 (en) * | 2013-05-08 | 2016-07-19 | The University of Denver and Regis University | Antibiotic and anti-parasitic agents that modulate class II fructose 1,6-bisphosphate aldolase |
| SI3030227T1 (sl) | 2013-08-07 | 2020-08-31 | Incyte Corporation | Dozirne oblike s podaljšanim sproščanjem za inhibitor JAK1 |
| MX2016002367A (es) | 2013-08-23 | 2016-10-28 | Incyte Corp | Compuestos de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim. |
| CA2943363A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US10799505B2 (en) | 2014-11-16 | 2020-10-13 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| EP3368039A1 (en) | 2015-10-26 | 2018-09-05 | The Regents of The University of Colorado, A Body Corporate | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| HUE068971T2 (hu) | 2016-04-04 | 2025-02-28 | Loxo Oncology Inc | (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid folyékony készítményei |
| PT3800189T (pt) | 2016-05-18 | 2023-07-27 | Array Biopharma Inc | Preparação de (s)-n-(5-((r)-2-(2,5- difluoropenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3- il)-3-hidroxipirrolidina-1-carboxamida |
| EP3512834A4 (en) * | 2016-09-14 | 2020-05-06 | Vanderbilt University | INHIBITION OF BMP SIGNALING, COMPOUNDS, COMPOSITIONS AND USES THEREOF |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| LT3746429T (lt) | 2018-01-30 | 2022-05-10 | Incyte Corporation | (1-(3-fluor-2-(trifluormetil)izonikotinil)piperidin-4-ono) gamybos būdai |
| WO2019178383A1 (en) | 2018-03-14 | 2019-09-19 | Vanderbilt University | Inhibition of bmp signaling, compounds, compositions and uses thereof |
| MY206999A (en) | 2018-03-30 | 2025-01-23 | Incyte Corp | Treatment of hidradenitis suppurativa using jak inhibitors |
| CN110833554B (zh) * | 2018-08-15 | 2022-03-08 | 广西梧州制药（集团）股份有限公司 | 吡唑并嘧啶衍生物在治疗自身免疫性甲状腺疾病的用途 |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| CR20210215A (es) | 2018-10-31 | 2021-06-17 | Gilead Sciences Inc | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| EP4192459A4 (en) * | 2020-08-05 | 2024-12-04 | The General Hospital Corporation | SALT-INDUCABLE KINASE INHIBITORS |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050239822A1 (en) * | 2002-10-08 | 2005-10-27 | Gruenenthal Gmbh | Substituted C-imiadazol[1,2-a] pyridin-3-yl-methylamines |
| US20050256309A1 (en) * | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands |
| EP1235825B1 (en) * | 1999-11-30 | 2006-01-25 | Pfizer Products Inc. | Novel benzoimidazole derivatives useful as antiproliferative agents |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU66502A (sh) * | 2000-03-06 | 2005-09-19 | Warner-Lambert Company | 5-alkilpirido(2,3-d)pirimidini, inhibitori tirozinkinaza |
| JP3729343B2 (ja) | 2000-04-27 | 2005-12-21 | アステラス製薬株式会社 | 縮合ヘテロアリール誘導体 |
| ATE386736T1 (de) * | 2000-09-11 | 2008-03-15 | Novartis Vaccines & Diagnostic | Verfahren zur herstellung von benzimidazol-2-yl - chinolinonderivaten |
| SE0100567D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
| EP1382603B1 (en) | 2001-04-26 | 2008-07-23 | Eisai R&D Management Co., Ltd. | Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof |
| DE60318198T2 (de) | 2002-05-02 | 2008-12-04 | Merck & Co., Inc. | Tyrosinkinase-hemmer |
| PA8580301A1 (es) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| US7205316B2 (en) * | 2004-05-12 | 2007-04-17 | Abbott Laboratories | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands |
| JP2008513508A (ja) | 2004-09-21 | 2008-05-01 | シンタ ファーマシューティカルズ コーポレーション | 炎症及び免疫に関連する用途に用いる化合物 |
| WO2006038111A1 (en) | 2004-10-07 | 2006-04-13 | Pfizer Products Inc. | Benzoimidazole derivatives useful as antiproliferative agents |
| WO2007115289A2 (en) | 2006-04-05 | 2007-10-11 | Novartis Ag | Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer |
| CA2682231A1 (en) * | 2007-03-28 | 2008-10-09 | Array Biopharma Inc. | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors |
| WO2010039825A2 (en) * | 2008-10-01 | 2010-04-08 | Array Biopharma Inc. | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS |
-
2008
- 2008-03-27 US US12/593,879 patent/US8138181B2/en not_active Expired - Fee Related
- 2008-03-27 AU AU2008237507A patent/AU2008237507B2/en not_active Ceased
- 2008-03-27 KR KR1020097022907A patent/KR101538179B1/ko not_active Expired - Fee Related
- 2008-03-27 EP EP08744440.2A patent/EP2137184B1/en active Active
- 2008-03-27 ES ES08744440T patent/ES2420113T3/es active Active
- 2008-03-27 UA UAA200910891A patent/UA101611C2/ru unknown
- 2008-03-27 MX MX2009010728A patent/MX2009010728A/es active IP Right Grant
- 2008-03-27 CN CN200880018702A patent/CN101679423A/zh active Pending
- 2008-03-27 HR HRP20130660AT patent/HRP20130660T1/hr unknown
- 2008-03-27 PT PT87444402T patent/PT2137184E/pt unknown
- 2008-03-27 DK DK08744440.2T patent/DK2137184T3/da active
- 2008-03-27 RS RS20130316A patent/RS52862B/sr unknown
- 2008-03-27 PL PL08744440T patent/PL2137184T3/pl unknown
- 2008-03-27 MY MYPI20094106A patent/MY157724A/en unknown
- 2008-03-27 CA CA2682981A patent/CA2682981C/en not_active Expired - Fee Related
- 2008-03-27 CN CN201310054054.1A patent/CN103214482B/zh not_active Expired - Fee Related
- 2008-03-27 JP JP2010502204A patent/JP5374492B2/ja not_active Expired - Fee Related
- 2008-03-27 NZ NZ580327A patent/NZ580327A/en not_active IP Right Cessation
- 2008-03-27 BR BRPI0809998A patent/BRPI0809998B8/pt not_active IP Right Cessation
- 2008-03-27 RU RU2009140407/04A patent/RU2467008C2/ru not_active IP Right Cessation
- 2008-03-27 WO PCT/US2008/058395 patent/WO2008124323A1/en not_active Ceased
- 2008-03-28 TW TW097111550A patent/TWI429434B/zh not_active IP Right Cessation
-
2009
- 2009-10-01 IL IL201300A patent/IL201300A0/en active IP Right Grant
- 2009-10-27 CO CO09120874A patent/CO6251377A2/es active IP Right Grant
- 2009-11-02 ZA ZA2009/07674A patent/ZA200907674B/en unknown
-
2013
- 2013-06-28 CY CY20131100527T patent/CY1114277T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1235825B1 (en) * | 1999-11-30 | 2006-01-25 | Pfizer Products Inc. | Novel benzoimidazole derivatives useful as antiproliferative agents |
| US20050239822A1 (en) * | 2002-10-08 | 2005-10-27 | Gruenenthal Gmbh | Substituted C-imiadazol[1,2-a] pyridin-3-yl-methylamines |
| US20050256309A1 (en) * | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2467008C2 (ru) | СОЕДИНЕНИЯ ИМИДАЗО[1,2-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ РЕЦЕПТОРНЫХ ТИРОЗИНКИНАЗ | |
| JP2010523576A5 (enExample) | ||
| AU2023201404B2 (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
| CN108349940B (zh) | 布鲁顿酪氨酸激酶抑制剂 | |
| JP7644139B2 (ja) | インダゾール系化合物及び関連使用方法 | |
| DK2686310T5 (en) | Benzodioxan-INHIBITORERAFLEUKOTRIEN PRODUCTION | |
| DK2651939T3 (en) | Substituted N- (1H-indazol-4-yl) imidazo [1,2-a] pyridine-3-carboxamide as Type-III-RECEPTOR-tyrosine kinase inhibitors | |
| CA2860765C (en) | Pyrazinecarboxamide compound | |
| CN114867727A (zh) | Tau蛋白靶向化合物及相关使用方法 | |
| KR102388312B1 (ko) | 아미노피리미딘 화합물, 이의 제조방법 및 용도 | |
| KR20170123631A (ko) | 벤즈아제핀 다이카복스아미드 화합물 | |
| CN110062761A (zh) | 取代的1H-咪唑并[4,5-b]吡啶-2(3H)-酮及其作为GLUN2B受体调节剂的用途 | |
| KR20250121029A (ko) | 두드러기 치료를 위한 야생형 c-kit 키나제 억제제로서의 n-페닐-피라졸로[1,5-a]피리딘-3-카르복사미드 유도체 | |
| JP2017531679A (ja) | キナーゼ阻害剤として有用なインドールカルボキシアミド | |
| KR20150118148A (ko) | Trk 저해 화합물 | |
| CN115557933B (zh) | 布鲁顿酪氨酸激酶及其突变体降解剂、组合物及应用 | |
| EP2885285A1 (en) | Pyrazole derivatives which inhibit leukotriene production | |
| JP2009533440A (ja) | Ｃｇｒｐ拮抗薬塩 | |
| CN105121439A (zh) | 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物 | |
| KR20180032611A (ko) | Tgf 베타 수용체 길항제 | |
| AU2020400010B2 (en) | Heterocyclic compounds as modulators of Stimulator of Interferon Genes (STING) | |
| TW202214233A (zh) | 可做為tlr9抑制劑之經取代雜芳基化合物 | |
| JP2023517539A (ja) | Ｒｎａ結合タンパク質またはｒｎａ修飾タンパク質を標的とする化合物 | |
| JP2022081710A (ja) | 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用 | |
| WO2020203609A1 (ja) | 掻痒を治療するためのｔ型カルシウムチャネル阻害剤の使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20210328 |